Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 2Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Pancreatic Neoplasms 1Lung Neoplasms 1Liver Neoplasms 1Kidney Neoplasms 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

Gemcitabine 358Fluorouracil 94Oxaliplatin 81Capecitabine 74130-nm albumin-bound paclitaxel 71Albumin-Bound Paclitaxel 70Radiotherapy 67Leucovorin 58Irinotecan 49Erlotinib Hydrochloride 47Cisplatin 44Bevacizumab 31pembrolizumab 30Radiosurgery 30Docetaxel 26Taxes 24Nivolumab 24Cetuximab 24Pancreaticoduodenectomy 20Drug Therapy 17folfirinox 16Cyclophosphamide 16Radiation 15Ipilimumab 13Endoscopic Ultrasound-Guided Fine Needle Aspiration 13Surgical Procedures, Operative 12Sorafenib 12Paclitaxel 12Neoadjuvant Therapy 12irinotecan sucrosofate 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Pancreatic Neoplasms × NIS-793 × Clear all
NCT02947165 2022-01-31

Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.

Novartis

Phase 1 Completed
120 enrolled
BreastGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Kidney Neoplasms, Liver Neoplasms, Lung Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡